


Antibiogo II



Area/Type: Medical R&D, Very Large Scale followed by an Incubator
Sponsor/Support: OCP/OCB & WACA
Length/Project Status: 3 years + 1 year; **ONGOING**



TRANSFORMATIONAL
INVESTMENT
CAPACITY

Project Summary

Problem

Antimicrobial Resistance (AMR) is recognized as a major threat to public health causing 700 000 annual deaths. AMR drivers are diverse and include: the irrational use of antibiotics by patients and physicians, the poor Infection Prevention Control measures that cause the spread of multidrug-resistant bacteria and the lack or **absence of cost-effective diagnostic tools** that can support targeted prescription and management of antibiotic use.

Proposed Solution

Following the development of Antibiogo, an **open-source application supporting non-expert laboratory technicians interpreting Antibiotic Susceptibility Tests**, to help doctors pre-scribe accurate antibiotics to their patients, phase II focuses on **establishing an organizational and financial model that supports Antibiogo** and potentially other MSF digital health tools under a unified regulatory backbone.



Potential Impact

- **Reduces mortality and morbidity** from sepsis, severe infections, and treatment failure
- **Improve MSF's broader digital health ecosystem** by pioneering a new access model for digital health tools

Viability

- **Building on an existing application** and the momentum of 3 years development work.
- Functions as a **comprehensive program addressing multiple dimensions of antimicrobial resistance.**

Risk Mitigation

- **Conducts ethical and reputational risk assessment** to mitigate misalignment between the sustainability model and MSF's humanitarian principles e.g., dual licensing seen as commercialization and inequitable or contrary to MSF principles.

Scalability

- Prioritizes **scale-up from onset** and positioning MSF not only as a leading actor in the global response to AMR, but also as a **pioneering legal manufacturer of digital health tools.**